Results from Figs. 1A and 1B demonstrated a significant reduction in CES1 mRNA expression across various human cancers, including bladder, cholangiocarcinoma, renal cell carcinoma, and endometrial cancer. This evidence concerns the gene CES1 and renal cell carcinoma.